Baduanjin Intervention in Clinical Studies After Coronary Revascularization Surgery
2026年5月19日 更新者：Liu Qiang
- To evaluate the efficacy and safety of the Baduanjin exercise programme in patients following coronary revascularisation surgery;
- To develop a traditional Chinese medicine (TCM) rehabilitation protocol and evaluation system for patients following coronary revascularisation surgery;
- To clarify the advantages of TCM rehabilitation in the post-operative management of coronary revascularisation surgery and to provide high-level evidence-based medical evidence for TCM rehabilitation protocols.
調査の概要
状態
まだ募集していません
詳細な説明
Patients who had undergone coronary revascularisation were selected as study subjects and divided into an intervention group (standard Western medical treatment + Baduanjin) and a control group (standard Western medical treatment + aerobic exercise). The intervention lasted 12 weeks, with follow-up assessments conducted at baseline (on the day of enrolment), 6 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks. The incidence of major adverse cardiovascular events was used as the primary efficacy endpoint, secondary efficacy endpoints included Traditional Chinese Medicine syndrome scores, echocardiography, Holter monitoring, the Minnesota Quality of Life Questionnaire, cardiac enzymes, blood lipids and blood glucose; safety endpoints comprised vital signs, complete blood count, liver and kidney function, and other adverse reactions and events.
Translated with DeepL.com (free version)
研究の種類
介入
入学 (推定)
310
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Liu Qiang, PhD
- 電話番号：+86 13588121905
- メール：19981011@zcmu.edu.cn
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Participants who meet the diagnostic criteria for coronary heart disease
- Participants who underwent successful percutaneous coronary intervention
- Participants aged between 18 and 80
- Participants of any gender
- Participants who have signed an informed consent form
Exclusion Criteria:
- Subjects with severe hepatic or renal impairment
- subjects with severe electrolyte disturbances
- subjects with severe haematological disorders or malignant tumours
- pregnant or breastfeeding women
- subjects with psychiatric disorders
- subjects with cognitive impairment (e.g. dementia, post-stroke cognitive impairment) that prevents them from understanding or carrying out exercise instructions
- Subjects scheduled to undergo repeat revascularisation surgery in the near future
- Subjects with other severe cardiovascular diseases such as uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block (without a pacemaker), acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, or acute aortic dissection
- Participants with acute pulmonary embolism or chronic lung disease accompanied by symptoms of dyspnoea (occurring at rest or with minimal exertion)
- Subjects with impaired limb mobility or who are unable to move independently;
- Subjects with Shy-Drager syndrome
- Subjects who have participated in a clinical trial involving other drugs or exercise interventions within the past month
- Subjects deemed by the investigator to have other conditions rendering them unsuitable for participation in the trial
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Experimental Group
Standardized Western medical treatment + Standardized Baduanjin rehabilitation training.
Standardised Baduanjin training was conducted under the supervision of a qualified doctor or physiotherapist.
Participants trained four times a week, performing the routine twice at each session.
Progress was monitored and guidance provided through the creation of a WeChat group and the distribution of video materials.
Participants received weekly guidance, either online or in person, and uploaded videos of their training sessions.
Throughout the study, all sessions were regularly monitored and feedback was provided to ensure correct instruction.
|
Standardised Baduanjin training was conducted under the supervision of a qualified doctor or physiotherapist.
Participants trained four times a week, performing the routine twice at each session.
Progress was monitored and guidance provided through the creation of a WeChat group and the distribution of video materials.
Participants received weekly guidance, either online or in person, and uploaded videos of their training sessions.
Throughout the study, all sessions were regularly monitored and feedback was provided to ensure correct instruction.
|
|
アクティブコンパレータ：Control Group
Standardized Western medical treatment + Aerobic exercise training.
Aerobic exercise training included climbing stairs, jogging, brisk walking and cycling.
The exercise intensity for the aerobic exercise group was monitored, with maximum heart rate estimated as 208 minus (0.7 × age).
Participants received weekly guidance, either online or in person, and uploaded videos of their training sessions.
Throughout the study, all sessions were regularly monitored and feedback was provided to ensure correct guidance.
|
Aerobic exercise training included climbing stairs, jogging, brisk walking and cycling.
The exercise intensity for the aerobic exercise group was monitored, with maximum heart rate estimated as 208 minus (0.7 × age).
Participants received weekly guidance, either online or in person, and uploaded videos of their training sessions.
Throughout the study, all sessions were regularly monitored and feedback was provided to ensure correct guidance.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of major cardiovascular adverse events
時間枠：From enrolment to 48 weeks of follow-up
|
Using medical record forms and clinical diagnostic criteria, assess the number of cases of the following cardiovascular adverse events: all-cause mortality, subacute in-stent thrombosis, perioperative myocardial infarction, recurrent myocardial infarction, recurrent unstable angina, repeat revascularisation, and readmission for angina or heart failure; and record the date of occurrence, basis for diagnosis, management measures, outcome (recovery/persistence/worsening/death), causality (definitely related/probably related/probably unrelated/definitely unrelated/cannot be determined) and the impact on the study (whether the patient withdrew or the study was unblinded).
Units: cases or categorical variables.
|
From enrolment to 48 weeks of follow-up
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
TCM Syndrome Score
時間枠：From enrolment to 48 weeks of follow-up
|
Using the 'Scoring Table for Syndromes in Traditional Chinese Medicine', the following symptoms were assessed: chest pain, chest tightness, palpitations, shortness of breath, exacerbation on exposure to cold, mental fatigue and physical weakness, spontaneous sweating, reluctance to speak, obesity, epigastric fullness and loss of appetite, gooseflesh, a dark purple complexion or lips, a sensation of heaviness in the head as if wrapped in a cloth, coughing up phlegm or wheezing in the throat, aversion to cold and cold limbs, hot flushes and night sweats, dry mouth and throat, pale conjunctiva of the eyelids, severe bitter taste in the mouth, and emotional depression or frequent sighing.
These 20 symptoms were each scored on a scale of 0-3 (0 = absent, 1 = mild, 2 = moderate, 3 = severe); simultaneously record bowel movements and urination, tongue quality, tongue shape, tongue coating, sublingual veins, pulse characteristics, and the qualitative classification of primary syndromes.
|
From enrolment to 48 weeks of follow-up
|
|
Echocardiogram
時間枠：Enrollment and 12-week follow-up
|
This study used echocardiography (ultrasound diagnostic equipment) to assess the following parameters: left ventricular ejection fraction (LVEF, %); left ventricular short-axis fraction of shortening (FS, %); left ventricular end-diastolic diameter (LVEDD, unit: mm), left ventricular end-systolic diameter (LVESD, unit: mm), left ventricular posterior wall thickness (LVPW, unit: mm), and interventricular septal thickness (IVS, unit: mm); simultaneously assess the following left ventricular diastolic function parameters: E/A ratio (unit: none, i.e. ratio) and mean E/e' ratio (unit: none) ; and record the overall assessment and conclusions, including major findings such as segmental wall motion abnormalities and reduced left ventricular diastolic function (qualitative description), as well as comparisons with previous examinations (newly developed/improved compared to previous findings/worsened compared to previous findings/no change/no comparable data available).
|
Enrollment and 12-week follow-up
|
|
Dynamic Electrocardiogram
時間枠：Enrollment and 12-week follow-up
|
This study assessed the following parameters using 24-hour Holter monitoring: mean, maximum and minimum heart rates and durations; total number of atrial premature beats (P' wave morphology), number of atrial tachycardia episodes, duration of atrial fibrillation/flutter (P wave replaced by f/F waves); total number of ventricular premature beats (QRS complex width ≥120 ms, without preceding P wave), number of paired ventricular premature beats and ventricular tachycardia episodes; longest RR interval and asystole/conduction block; amplitude and duration of ST-segment depression events (measured 80 ms after the J point); heart rate variability (SDNN); and P-wave width, PR interval, QRS width, QT interval and QTc interval (Bazett formula) measured during sinus rhythm.
|
Enrollment and 12-week follow-up
|
|
Minnesota Quality of Life Scale
時間枠：From enrolment to 48 weeks of follow-up
|
The standardised Minnesota Heart Failure Quality of Life Questionnaire was completed by the patients themselves or with the assistance of the investigators to quantitatively assess their quality of life.
The Minnesota Health-Related Quality of Life Questionnaire (MLHFQ) is a standardised tool used to quantify the overall impact of heart failure on patients' physical, emotional and social functioning.
The total score ranges from 0 to 105; a higher score indicates poorer quality of life, whilst a lower score indicates better health-related quality of life.
A total score below 24 is considered an indicator of good quality of life.
|
From enrolment to 48 weeks of follow-up
|
|
Cardiac enzymes
時間枠：Enrollment and 12-week follow-up
|
Peripheral venous blood samples were collected from patients at each follow-up visit and analysed biochemically by the central laboratory to record levels of cardiac enzymes, including creatine kinase isoenzymes.
|
Enrollment and 12-week follow-up
|
|
blood lipids
時間枠：Enrollment and 12-week follow-up
|
Blood samples were collected from patients' peripheral veins at each visit and sent to the central laboratory for biochemical analysis to determine levels of four lipid parameters, including total cholesterol.
|
Enrollment and 12-week follow-up
|
|
Fasting blood glucose
時間枠：Enrollment and 12-week follow-up
|
Peripheral venous blood samples were collected from patients at each visit, and biochemical analyses were carried out by the central laboratory, with the results recorded.
|
Enrollment and 12-week follow-up
|
|
Peripheral venous blood samples were collected from patients at each visit, and biochemical analyses were carried out by the central laboratory, with the results recorded.
時間枠：Enrollment and 12-week follow-up
|
Peripheral venous blood samples were collected from patients at each visit, and biochemical analyses were carried out by the central laboratory, with the results recorded.
|
Enrollment and 12-week follow-up
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Red blood cell count
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken for a complete blood count at the time points specified in the study.
|
Enrollment and 12-week follow-up
|
|
Haemoglobin concentration
時間枠：Enrollment and 12-week follow-up
|
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
|
Enrollment and 12-week follow-up
|
|
White blood cell count
時間枠：Enrollment and 12-week follow-up
|
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
|
Enrollment and 12-week follow-up
|
|
Platelet count
時間枠：Enrollment and 12-week follow-up
|
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
|
Enrollment and 12-week follow-up
|
|
Haematocrit
時間枠：Enrollment and 12-week follow-up
|
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
|
Enrollment and 12-week follow-up
|
|
Alanine transaminase
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Aspartate transaminase
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Alkaline phosphatase
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Potassium
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Sodium
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Total bilirubin
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Blood urea nitrogen
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Creatinine
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Uric acid
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Homocysteine
時間枠：Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年7月1日
一次修了 (推定)
2028年6月30日
研究の完了 (推定)
2028年12月31日
試験登録日
最初に提出
2026年5月12日
QC基準を満たした最初の提出物
2026年5月19日
最初の投稿 (実際)
2026年5月27日
学習記録の更新
投稿された最後の更新 (実際)
2026年5月27日
QC基準を満たした最後の更新が送信されました
2026年5月19日
最終確認日
2026年5月1日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
IPD プランの説明
Firstly, the informed consent forms obtained from participants prior to the commencement of the study did not include any provisions authorising the open sharing of de-identified individual data on public platforms.
Out of strict respect for participants' right to privacy and the scope of their informed consent, it is not appropriate to make the data publicly available.
Secondly, as this study involves multi-centre collaboration, the ownership of data and the mechanisms for data sharing across the various sub-centres have not yet been uniformly clarified in the collaboration agreement.
Furthermore, the individualised data collected in this trial-such as Traditional Chinese Medicine (TCM) syndrome scores and tongue and pulse characteristics-lacks recognised public data-sharing standards for its de-identification and standardisation.
Direct disclosure could lead to the data being misinterpreted or misused.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。